Ryan J Koene1, Sithu Win2, Niyada Naksuk2, Sirtaz N Adatya3, Andrew N Rosenbaum4, Ranjit John5, Peter M Eckman3. 1. Division of Cardiovascular Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. Electronic address: ryankoene@gmail.com. 2. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. 3. Division of Cardiovascular Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 4. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 5. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND: HAS-BLED and CHA₂DS₂-VASc scores predict bleeding in patients on anticoagulation and thromboembolic (TE) risk in patients with atrial fibrillation, respectively. We hypothesized that these scores would be predictive of bleeding and TE complications following continuous-flow ventricular assist device (CF-VAD) implantation. METHODS AND RESULTS: Baseline HAS-BLED and CHA2DS2-VASc scores were retrospectively determined for 173 consecutive patients who underwent HeartMate II CF-VAD implantation at a single center from 2005 to 2011. Forty-three patients had bleeding (24.9%) and 22 had TE (12.7%) events over a 290 patient-year follow-up period. The mean ± SD HAS-BLED scores were 2.7 ± 1.0 and 1.9 ± 1.1 (P < .0001) in patients with and without bleeding, respectively. The CHA₂DS₂-VASc scores were 3.6 ± 1.4 and 2.9 ± 1.5 (P = .03) in patients with and without TE events, respectively. A HAS-BLED score of ≥ 3 was associated with a significantly higher risk of bleeding events compared with a score of <3 (42% vs 15%, respectively; hazard ratio [HR] 3.40, 95% confidence interval [CI] 1.82-6.32; P < .001). A CHA₂DS₂-VASc score of ≥ 3 was associated with a higher risk of TE events compared with a score of <3 (18% vs 4%, respectively; HR 4.02, 95% CI 1.19-13.6; P = .025). CONCLUSIONS: Baseline HAS-BLED and CHA₂DS₂-VASc scores of ≥ 3 conferred significantly higher risks of bleeding and TE, respectively, following HeartMate II implantation.
BACKGROUND: HAS-BLED and CHA₂DS₂-VASc scores predict bleeding in patients on anticoagulation and thromboembolic (TE) risk in patients with atrial fibrillation, respectively. We hypothesized that these scores would be predictive of bleeding and TE complications following continuous-flow ventricular assist device (CF-VAD) implantation. METHODS AND RESULTS: Baseline HAS-BLED and CHA2DS2-VASc scores were retrospectively determined for 173 consecutive patients who underwent HeartMate II CF-VAD implantation at a single center from 2005 to 2011. Forty-three patients had bleeding (24.9%) and 22 had TE (12.7%) events over a 290 patient-year follow-up period. The mean ± SD HAS-BLED scores were 2.7 ± 1.0 and 1.9 ± 1.1 (P < .0001) in patients with and without bleeding, respectively. The CHA₂DS₂-VASc scores were 3.6 ± 1.4 and 2.9 ± 1.5 (P = .03) in patients with and without TE events, respectively. A HAS-BLED score of ≥ 3 was associated with a significantly higher risk of bleeding events compared with a score of <3 (42% vs 15%, respectively; hazard ratio [HR] 3.40, 95% confidence interval [CI] 1.82-6.32; P < .001). A CHA₂DS₂-VASc score of ≥ 3 was associated with a higher risk of TE events compared with a score of <3 (18% vs 4%, respectively; HR 4.02, 95% CI 1.19-13.6; P = .025). CONCLUSIONS: Baseline HAS-BLED and CHA₂DS₂-VASc scores of ≥ 3 conferred significantly higher risks of bleeding and TE, respectively, following HeartMate II implantation.
Authors: Robert J Stanton; Mark H Eckman; Daniel Woo; Charles J Moomaw; Mary Haverbusch; Matthew L Flaherty; Dawn O Kleindorfer Journal: Stroke Date: 2020-01-31 Impact factor: 7.914
Authors: Walter M van den Bergh; Annemieke Oude Lansink-Hartgring; Abram L van Duijn; Annemarie E Engström; Jaap R Lahpor; Arjen J C Slooter Journal: J Cardiothorac Surg Date: 2015-10-15 Impact factor: 1.637
Authors: Andrew Melehy; Gillian O'Connell; Yuming Ning; Paul Kurlansky; Yuji Kaku; Veli Topkara; Melana Yuzefpolskaya; Paolo C Colombo; Gabriel Sayer; Nir Uriel; Yoshifumi Naka; Koji Takeda Journal: Interact Cardiovasc Thorac Surg Date: 2022-03-31
Authors: Christiaan F J Antonides; Yunus C Yalcin; Kevin M Veen; Rahatullah Muslem; Theo M M H De By; Ad J J C Bogers; Finn Gustafsson; Kadir Caliskan Journal: Eur J Cardiothorac Surg Date: 2022-05-02 Impact factor: 4.534
Authors: Jasmin S Hanke; Günes Dogan; Leonard Wert; Marcel Ricklefs; Jan Heimeshoff; Anamika Chatterjee; Christina Feldmann; Axel Haverich; Jan D Schmitto Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895